stomatin like 1Genealiases: SLP-1 · STORP · hUNC-24
Q-omics provides the consensus-scored STOML1 profile across patient tissues and cancer cell-line models. STOML1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, STOML1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, STOML1 RNA expression shows 17,502 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, KIRC, and TGCT as cancer lineages where STOML1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STOML1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STOML1 survival associations across molecular data types. STOML1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STOML1 RNA expression–survival associations across cancer types. High STOML1 expression shows unfavorable associations in MESO, BLCA and GBM, but favorable associations in ESCA, UCS and DLBC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for STOML1 RNA expression.
This table summarizes STOML1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for STOML1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STOML1 shows lower tumor expression in THCA and higher tumor expression in KIRC, HNSC, COAD, LIHC and KIRP. The KIRC box plot shows higher STOML1 RNA expression in tumor versus normal tissue (log2 FC = +0.800, t-test p < 0.001).
This table shows molecular features associated with STOML1 in patient tissues and cancer cell lines. In patient samples, STOML1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, STOML1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and CNS.
